The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Patients with systemic lupus erythematosus with a history of cutaneous lupus erythematosus are more likely to have high ...

The frequent exclusion of such patients from trials makes real-world data like these valuable for clinicians, says Eric ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...

There was a shorter time between treatments in the preoperative SRT arm. Preoperative stereotactic radiation therapy (SRT) could expedite treatment for cancer patients with brain metastases and is as ...

One major reason why the U.S. and Western Europe have seen dramatic population increase over the last 200-plus years, Aaby ...

InMode Ltd. (NASDAQ:INMD) is one of the best undervalued medical device stocks to buy now. In a report released on July 10, ...

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of geographic atrophy (GA). 1 ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...